Drug Trial Radar · NCT04678739
Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial
Last checked: Nov 19, 2026Latest source record: Apr 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
205
Actual
Start
Aug 15, 2020
Primary completion
Jan 30, 2021
Study completion Feb 10, 2021
Sponsor
- Lead sponsor
- M Abdur Rahim Medical College and HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- First Affiliated Hospital Xi'an Jiaotong University; Cox's Bazar 250 Bed District Sadar Hospital; Chattogram General Hospital
- First posted
- Dec 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized clinical trial was designed and intended to evaluate the efficacy of Remdesivir and Tocilizumab as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavirus disease 2019 (COVID-19). Our aim is to find the best option for the treatment and management of ARDS in COVID-19 patients.
Conditions
- Covid19
- Covid-19 ARDS
Interventions
RemdesivirDrug
Remdesivir 100 IV Infusion as a lyophilized powder
TocilizumabDrug
Actemra IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Clinical Improvement (TTCI)Time frame: Following randomization 30 days.
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Chattogram General Hospital
Chittagong, Bangladesh
Cox's Bazar 250 Bed District Sadar Hospital
Cox’s Bāzār, Bangladesh
M. Abdur Rahim Medical College Hospital
Dinajpur, Bangladesh
M. Abdur Rahim Medical College Hospital
Dinajpur, Bangladesh
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.